Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.30 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572668 | 1.00 | CNR2 (0.31) | CNR2CRBNMEN1KMT2ACYP2A6 | |
| SCHEMBL4572667 | 1.00 | CNR2 (0.31) | CNR2CRBNMEN1KMT2ACYP2A6 | |
| SCHEMBL7541027 | 1.00 | CNR2 (0.31) | CNR2CRBNMEN1KMT2ACYP2A6 | |
| SCHEMBL4572664 | 1.00 | CNR2 (0.31) | CNR2CRBNMEN1KMT2ACYP2A6 | |
| SCHEMBL6756999 | 1.00 | CNR2 (0.31) | CNR2CRBNMEN1KMT2ACYP2A6 | |
| SCHEMBL9170533 | 0.68 | CRBN (0.33) | CNR2CRBNCYP2A6CYP2A13ALDH1A1 | |
| SCHEMBL9170854 | 0.68 | CRBN (0.33) | CNR2CRBNCYP2A6CYP2A13ALDH1A1 | |
| SCHEMBL2474875 | 0.64 | TSHR (0.46) | CNR2CRBNCYP2A6CYP2A13ALDH1A1 | |
| SCHEMBL19366475 | 0.64 | CYP2A6 (0.32) | CYP2A6CYP2A13ALDH1A1TSHR | |
| SCHEMBL12985257 | 0.64 | CYP2A6 (0.32) | CYP2A6CYP2A13ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012054527-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | CNR2 164/4885CRBN 1037/4885MEN1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.